Loading
A phase 3 trial of Talquetamab, Daratumumab, Pomalidomide in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment is a phase 3 interventional study registered as NCT05455320 by Janssen Research & Development, LLC, with 864 participants enrolled, started 2022-10-13 and due to reach its primary completion in 2027-07-30. Interventions recorded: Talquetamab, Daratumumab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Talquetamab, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Talquetamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone.
Shares Pomalidomide, Daratumumab, Dexamethasone, Johnson & Johnson.